These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 793499)

  • 21. [Results and prognostic factors in the treatment of chronic active hepatitis with prednisone and azathioprine].
    Jorge AD; Sánchez D
    Acta Gastroenterol Latinoam; 1985; 15(4):233-41. PubMed ID: 3842554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
    Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
    Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current and future treatments of autoimmune hepatitis.
    Czaja AJ
    Expert Rev Gastroenterol Hepatol; 2009 Jun; 3(3):269-91. PubMed ID: 19485809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunosuppressive long-term treatment of chronic aggressive hepatitis].
    Schimmelpfennig W; Schneider G; Wagner K; Wack R; Lunzenauer K
    Z Gesamte Inn Med; 1975 Dec; 30(24):273 concl. PubMed ID: 1221650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology.
    Czaja AJ; Davis GL; Ludwig J; Baggenstoss AH; Taswell HF
    Gastroenterology; 1983 Sep; 85(3):713-7. PubMed ID: 6192038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Autoimmune hepatitis: clinical forms and related factors to their response to treatment].
    Dávalos M; Román R; Bustios C; Zumaeta E; Yabar A
    Rev Gastroenterol Peru; 2004; 24(4):305-13. PubMed ID: 15614298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Indications, method and effectiveness of immunosuppressive treatment in chronic active hepatopathies. I. Changes in the general dynamics of the disease. II. Slowing-down of the chronicization process].
    Nicolaescu T; Stoiculescu P; Bittman E; Bordeianu A; Gheorghe N; Pintilescu V; Metz L
    Med Interna (Bucur); 1974 Apr; 26(4):453-64. PubMed ID: 4839352
    [No Abstract]   [Full Text] [Related]  

  • 29. [Therapy of chronic hepatitis (author's transl)].
    Arnold W; Meyer zum Büschenfelde KH
    Leber Magen Darm; 1981 Apr; 11(2):73-80. PubMed ID: 6164895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of immunosuppressive treatment: Prognosis in chronic active hepatitis.
    Pelikán V; Seidlová V; Sánová J; Komenda S
    Acta Hepatogastroenterol (Stuttg); 1975 Aug; 22(4):210-4. PubMed ID: 1179942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis.
    Heurkens AH; Westedt ML; Breedveld FC
    Arch Intern Med; 1991 Nov; 151(11):2249-54. PubMed ID: 1953230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis.
    Soloway RD; Summerskill WH; Baggenstoss AH; Geall MG; Gitnićk GL; Elveback IR; Schoenfield LJ
    Gastroenterology; 1972 Nov; 63(5):820-33. PubMed ID: 4538724
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of chronic hepatitis.
    Mistilis SP; Lam KC
    Prog Liver Dis; 1972; 4():419-32. PubMed ID: 4569006
    [No Abstract]   [Full Text] [Related]  

  • 35. Chronic active liver disease reexamined: prognosis hopeful.
    Summerskill WH
    Gastroenterology; 1974 Mar; 66(3):450-64. PubMed ID: 4591728
    [No Abstract]   [Full Text] [Related]  

  • 36. Individual therapy-dependent prognosis based on data from controlled clinical trials in chronic liver disease.
    Christensen E
    Dan Med Bull; 1988 Apr; 35(2):167-82. PubMed ID: 3282812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis BS antigen.
    Schalm SW; Summerskill WH; Gitnick GL; Elveback LR
    Gut; 1976 Oct; 17(10):781-6. PubMed ID: 793956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of glomerulonephritis].
    Kröger E; Klinkmann H; Schmitt E; Ratner MJ; Tomilina NA
    Z Urol Nephrol; 1979 Jan; 72(1):41-7. PubMed ID: 425735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [2 patients with chronic hepatitis].
    Sauerwein HP
    Ned Tijdschr Geneeskd; 1978 Apr; 122(17):596-600. PubMed ID: 652070
    [No Abstract]   [Full Text] [Related]  

  • 40. Chronic active liver disease with common variable hypogammaglobulinemia.
    Solley GO; Dickson ER; Gleich GJ; Stobo JD
    Mayo Clin Proc; 1979 Feb; 54(2):127-30. PubMed ID: 762994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.